{"id":"NCT00105196","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"A Study of Aripiprazole in Patients With Major Depressive Disorder","officialTitle":"A Study of Aripiprazole in Patients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-03","primaryCompletion":"2008-03","completion":"2008-03","firstPosted":"2005-03-10","resultsPosted":"2009-05-18","lastUpdate":"2013-12-02"},"enrollment":349,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Aripiprazole+ ADT","otherNames":["Abilify"]},{"type":"DRUG","name":"Placebo+ ADT","otherNames":[]}],"arms":[{"label":"A1","type":"EXPERIMENTAL"},{"label":"A2","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess the safety and efficacy of aripiprazole to placebo as adjunctive treatment to an assigned open-label marketed antidepressant therapy (ADT) in patients with Major Depressive Disorder who demonstrate an incomplete response to a prospective eight week trial of the same assigned open-label marketed antidepressant therapy.","primaryOutcome":{"measure":"Mean Change in the Montgomery Ã…sberg Depression Rating Scale (MADRS)","timeFrame":"Baseline (Week 8) and Week 14","effectByArm":[{"arm":"Aripiprazole + ADT","deltaMin":-10.12,"sd":0.74},{"arm":"Placebo + ADT","deltaMin":-6.39,"sd":0.74}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":null},"locations":{"siteCount":34,"countries":["United States"]},"refs":{"pmids":["19407731","24766999","23585999","23585997","23106023","21731833"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":176},"commonTop":["AKATHISIA","HEADACHE","RESTLESSNESS","UPPER RESPIRATORY TRACT INFECTION","INSOMNIA"]}}